Small molecule p300/catenin antagonist enhances hematopoietic recovery after radiation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28486541.
- Also identified by DOI 10.1371/journal.pone.0177245 and PMC identifier 5423697.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
There is currently no FDA approved therapeutic agent for ARS mitigation post radiation exposure. Here we report that the small molecule YH250, which specifically antagonizes p300/catenin interaction, stimulates hematopoiesis in lethally or sublethally irradiated mice. A single administration of YH250 24 hours post irradiation can significantly stimulate HSC proliferation, improve survival and accelerate peripheral blood count recovery. Our studies suggest that promotion of the expansion of the remaining HSC population via stimulation of symmetric non-differentiative proliferation is at least part of the mechanism of action.
Medical subject headings
- Catenins
- Hematopoiesis
- Heterocyclic Compounds, 2-Ring
- Radiation Injuries
- p300-CBP Transcription Factors